(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

CELEMICS

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: United States

Quick snapshot

CELEMICS

ST13

US500000098018569

Class

5, 42

Filing

98018569

Registration

7845163

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

27

Latest update

06/24/2025

Trademark type

Combined

Nice classes

5, 42

Filing date

05/30/2023

Registration date

06/24/2025

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

06/24/2025

Last transaction

06/24/2025

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

02/20/2025

First use in commerce

02/20/2025

Drawing code

3

Owner type

03

Owner location

Seoul,, KR

Examiner

LIU, PHILIP HUAI-EN

Law office

L90

Current location

PUBLICATION AND ISSUE SECTION

Mark description

The mark consists of the word "CELEMICS" with a helix to the left of the word.

Holders and representatives

Holders

CELEMICS, Inc.

Representatives

minchul yang STIP LAW GROUP

Technical classification

Nice Classes

Class 5Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Biotechnological preparationsreagents for medical purposes; pharmaceutical preparations for activating cellular function for the treatment of cancerinfectious diseaseautoimmune diseasecardiovascular diseaseallergy; chemical preparations for pharmaceutical purposesfor cancerinfectious diseaseautoimmune diseasecardiovascular diseaseallergy; chemical preparations for medical purposesfor cancerinfectious diseaseautoimmune diseasecardiovascular diseaseallergy; siccatives being drying agents for medical purposes; reagents for in-vitro laboratory use for medical purposes; cleansing solutions for medical use; reagents for medical use; drugs for medical purposespharmaceutical preparations for the treatment of cancerinfectious diseaseautoimmune diseasecardiovascular diseaseallergy; enzymes for medical purposes; enzyme preparations for medical purposes; nucleic acid sequences for medical and veterinary purposes; chemical preparations for use in DNA analysis for medical purposesfor cancerinfectious diseaseautoimmune diseasecardiovascular diseaseallergy; in vitro diagnostic preparations for medical purposes; diagnostic test reagents for medical or veterinary purposes; biological and chemical reagents for medical or veterinary purposes; reagents for use in medical genetic testing; reagents for use in veterinary genetic testing.

Class 42

Research and development of DNA chips; structural and functional analysis of genomes; scientific laboratory services; advisory services relating to scientific research; providing information relating to scientific research; advisory services relating to biotechnology; research relating to biotechnology; biological research services; biochemical analysis; biochemistry research services; scientific research in the field of gene analysis; customized genetic scientific research; pharmaceutical research; medical research; clinical research in the field of oncologycardiovascular disease neurologyimmunologygenomics; blood testing for scientific research purposes; consultancy in analysis of biology sequence processing for medical research purposes; consultancy in analysis of genomics for medical research purposes; scientific research in the fields of biomedicine; scientific research for medical purposes in the field of cancerous diseases; scientific research for medical purposes in the area of cancerous diseases; chemical research; research for medical productsmedical research; scientific research in the nature of conducting clinical trials for others in the field of oncologycardiovascular diseaseneurologyimmunologygenomics; biotechnology research; biochemical research; providing information of scientific research.

Publications

History of USPTO decisions and trademark events.

27 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

06/24/2025

R.PR

REGISTERED-PRINCIPAL REGISTER

06/24/2025

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

06/04/2025

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

06/04/2025

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

06/03/2025

SUPC

STATEMENT OF USE PROCESSING COMPLETE

06/02/2025

EISU

TEAS STATEMENT OF USE RECEIVED

03/10/2025

IUAF

USE AMENDMENT FILED

03/09/2025

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

09/24/2024

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

07/30/2024

PUBO

PUBLISHED FOR OPPOSITION

07/30/2024

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

07/10/2024

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

06/12/2024

XAEC

EXAMINER'S AMENDMENT ENTERED

06/12/2024

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

06/12/2024

GNEA

EXAMINERS AMENDMENT E-MAILED

06/12/2024

CNEA

EXAMINERS AMENDMENT -WRITTEN

06/12/2024

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

05/27/2024

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

05/27/2024

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

05/27/2024

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

03/01/2024

GNRT

NON-FINAL ACTION E-MAILED

03/01/2024

CNRT

NON-FINAL ACTION WRITTEN

03/01/2024

DOCK

ASSIGNED TO EXAMINER

02/22/2024

MDSC

NOTICE OF DESIGN SEARCH CODE E-MAILED

06/30/2023

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

06/29/2023

NWAP

NEW APPLICATION ENTERED

06/02/2023

Continuous trademark protection

Get notified about every new filing that threatens CELEMICS or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.